• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Healthcare·6496.TWO
Share

Excelsior Biopharma Inc. Stocks

NT$ 23.9Last Updated 11.06.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 36.19M

NT$ 23.9
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Excelsior Biopharma Inc., established in 1988 and headquartered in Taipei, Taiwan, functions as a pharmaceutical enterprise with a global market presence, encompassing Taiwan, China, and other international regions. The company offers a comprehensive range of healthcare solutions, including prescription and over-the-counter medications, medical devices, nutritional supplements, and various medical supplies. Excelsior addresses numerous therapeutic areas such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, otorhinolaryngology, and infectious disease management. Its product line also features specialized diagnostic kits under the Actim brand for identifying conditions like influenza virus, fecal occult blood, acute pancreatitis, and for assessing preterm or full-week delivery and early membrane rupture. Moreover, the company provides oral hygiene products, including toothpaste, mouthwash, and gels, under the Oral7 name. Beyond product sales, Excelsior is involved in the import and export of active pharmaceutical ingredients, as well as engaging in technological research, facilitating pharmaceutical technology transfer, and participating in collaborative development and improvement initiatives. The company adopted its current name, Excelsior Biopharma Inc., in June 2003, having previously been known as Excelsior Enterprise Co., Ltd.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.06.2026 22:46

Trump canceled planned new strikes on Iran. Oil below $90 per barrel

11.06.2026 22:30

Wall Street assessed the potential of SpaceX stock: optimists expect a 40% increase from the IPO price

11.06.2026 21:39

Bezos' AI startup has increased its valuation to $41 billion, what do we know about it?

11.06.2026 20:51

Retail investors are willing to buy back more than $70 billion worth of SpaceX stock - Bloomberg

11.06.2026 20:19

Emirates has come up with a way to bring tourists back to Dubai. What does it offer?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026